HGS004

HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004) ) -resistant strains. HGS004 can be used for HIV-1 infections research[1][2].

Product Specifications

UNSPSC

12352100

Target

CCR; HIV

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection

References & Citations

[1]Latinovic O, et al. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology. 2011 Mar 1;411 (1) :32-40. |[2]Lalezari J, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis. 2008 Mar 1;197 (5) :721-7.